HC Wainwright Has Lowered Expectations for Unity Biotechnology (NASDAQ:UBX) Stock Price

Posted by Eileen French on Mar 24th, 2025

Unity Biotechnology (NASDAQ:UBX – Get Free Report) had its price objective cut by analysts at HC Wainwright from $8.00 to $4.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 233.33% from the company’s current price.

Separately, Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Unity Biotechnology in a research note on Monday, March 10th.

Get Our Latest Stock Report on Unity Biotechnology

Unity Biotechnology Price Performance

NASDAQ:UBX traded down $0.63 during trading hours on Monday, reaching $1.20. 1,388,598 shares of the company were exchanged, compared to its average volume of 108,235. The business has a 50 day moving average of $1.92 and a 200 day moving average of $1.51. The company has a market capitalization of $20.24 million, a P/E ratio of -0.92 and a beta of 1.02. Unity Biotechnology has a 1-year low of $0.94 and a 1-year high of $3.10.

Institutional Investors Weigh In On Unity Biotechnology

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC increased its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 9.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 163,242 shares of the company’s stock after buying an additional 14,199 shares during the quarter. Geode Capital Management LLC owned 0.97% of Unity Biotechnology worth $240,000 at the end of the most recent reporting period. Institutional investors own 29.49% of the company’s stock.

About Unity Biotechnology

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.